SCHEMBL6799713

SCHEMBL6799713

COc1cccc(C=C2N=C(c3ccccc3)OC2=O)c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.71
ALDH1A1 P00352 4/20 0.70
KDM4E B2RXH2 3/20 0.70
GAA P10253 1/20 0.70
NPSR1 Q6W5P4 1/20 0.70
DAPK3 O43293 4/20 0.69
MEN1 O00255 3/20 0.67
KMT2A Q03164 3/20 0.67
TNNI3 P19429 1/20 0.67
CRHBP P24387 1/20 0.67
TNNT2 P45379 1/20 0.67
TNNC1 P63316 1/20 0.67
CRHR2 Q13324 1/20 0.67
MAPT P10636 2/20 0.62
HPGD P15428 2/20 0.60
NPC1 O15118 1/20 0.60
RAB9A P51151 1/20 0.60
LMNA P02545 1/20 0.59
NOTUM Q6P988 1/20 0.56
PLCG2 P16885 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6799710 1.00 POLB (0.71) POLBALDH1A1KDM4EGAANPSR1
SCHEMBL10599141 0.90 DAPK3 (0.60) POLBALDH1A1KDM4EGAANPSR1
SCHEMBL6789689 0.86 ALDH1A1 (0.64) POLBALDH1A1KDM4EGAANPSR1
SCHEMBL6789685 0.86 ALDH1A1 (0.64) POLBALDH1A1KDM4EGAANPSR1
SCHEMBL6795524 0.85 ALDH1A1 (0.67) POLBALDH1A1KDM4EGAANPSR1
SCHEMBL6795520 0.85 ALDH1A1 (0.67) POLBALDH1A1KDM4EGAANPSR1
SCHEMBL6796548 0.85 MEN1 (0.67) POLBALDH1A1KDM4EDAPK3MEN1
SCHEMBL15421524 0.85 MEN1 (0.67) POLBALDH1A1KDM4EDAPK3MEN1
SCHEMBL6796550 0.85 MEN1 (0.67) POLBALDH1A1KDM4EDAPK3MEN1
SCHEMBL6795837 0.83 DAPK3 (0.67) POLBALDH1A1KDM4EDAPK3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US claimed
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis APP, PSEN1, PSEN2 POLB 2537/4885ALDH1A1 905/4885KDM4E 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.